Clinical Trials
Study Title:
A Phase II Open Label, Study of IMMU 132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti PD 1/PD L1 Based Immunotherapy
|
For more information about the trial above please contact the study team:
Medical University of South Carolina
Principal Investigator, Theodore Gourdin, at gourdith@musc.edu.
Study Coordinator, Carly Fecio, at fecio@musc.edu.
Trial opened at the following institutions: Medical University of South Carolina |